Patents by Inventor Ross Rabin

Ross Rabin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met
    Publication number: 20090075922
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: May 14, 2007
    Publication date: March 19, 2009
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Publication number: 20060148748
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: December 19, 2005
    Publication date: July 6, 2006
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Publication number: 20030049644
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: February 4, 2002
    Publication date: March 13, 2003
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Patent number: 6344321
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 5, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold